Containment Packaging Protein RNA 
Pharmaceutical Technology
DECEMBER 9, 2022
Beyond our expertise in small molecules, we have built a solid reputation with biopharmaceutical companies for the characterisation and analysis of monoclonal antibodies, therapeutic proteins and biosimilars. Ribonucleic acid (RNA) based technologies are among many innovative approaches explored to tackle the Covid-19 pandemic.
Pfizer
AUGUST 15, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. FDA Emergency Use Authorization Statement. 07.27.2022.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
JANUARY 27, 2023
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus.
Drug Discovery World
MAY 2, 2023
Bacterial RNA is replaced by a synthetic guide RNA (gRNA) that can recognise a specific target DNA sequence. These modifications lead to alterations in the function of the proteins expressed by these genes, manifesting in cellular processes dependent on those proteins. CRISPR libraries: Why do we need them?
The Pharma Data
SEPTEMBER 1, 2020
COVID-19 testing solutions that provide healthcare professionals and patients with a quick answer regarding their infection status are critical to contain the community-spread of the COVID-19 virus. SARS-CoV-2 Rapid Antigen Test package insert [2] European Centre for Disease Prevention and Control. References [1] Roche Diagnostics Ltd.
The Pharma Data
MARCH 20, 2021
Coronaviruses are RNA viruses and include common human coronaviruses, severe acute respiratory syndrome-CoV (SARS-CoV), Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV-2 ( 1 ). Nucleocapsid protein from SARS patients was abundant enough to be detected in clinical samples using an ELISA approach ( 20 ). INTRODUCTION.
XTalks
FEBRUARY 11, 2021
The drugmaker is targeting various steps in the manufacturing process, beginning right at the DNA stage, which is required as the template from which the mRNA for the SARS-CoV-2 spike protein in the vaccine is made. The RNA is transcribed from DNA in 40-liter vessels containing enzymes and chemicals over the course of three to four days.
Expert insights. Personalized for you.
130 
Let's personalize your content